Full Text
PND1 ASSESSING THE NET CLINICAL BENEFIT AND ABSOLUTE RISK REDUCTION OF DISEASE MODIFYING DRUGS IN RELAPSING REMITTING MULTIPLE SCLEROSIS

Abstract

Authors

A AL-Sabbagh R Bennett R Glanzman

Back to Volume 10, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×